Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0OQ3L
|
|||
Former ID |
DNC001342
|
|||
Drug Name |
SL65.0472
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Discontinued in Phase 2 | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C24H24FN5O2S
|
|||
Canonical SMILES |
C1CN(CCN1CCC2=CC(=O)N(C3=C2C=CC(=C3)F)CC(=O)N)C4=NC=CC5=C4C=CS5
|
|||
InChI |
1S/C24H24FN5O2S/c25-17-1-2-18-16(13-23(32)30(15-22(26)31)20(18)14-17)4-7-28-8-10-29(11-9-28)24-19-5-12-33-21(19)3-6-27-24/h1-3,5-6,12-14H,4,7-11,15H2,(H2,26,31)
|
|||
InChIKey |
JDLYOFUDIKMYBL-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 189003-92-7
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | 5-HT 2A receptor (HTR2A) | Target Info | Modulator | [2] |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Gap junction | ||||
Serotonergic synapse | ||||
Inflammatory mediator regulation of TRP channels | ||||
Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
Reactome | Serotonin receptors | |||
G alpha (q) signalling events | ||||
WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | |||
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
SIDS Susceptibility Pathways | ||||
Monoamine GPCRs | ||||
GPCRs, Class A Rhodopsin-like | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014358) | |||
REF 2 | Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.Thromb Haemost.2001 Mar;85(3):521-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.